Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Five Supplementary Documents For Essential Drug System To Be Out Within Three Months

This article was originally published in PharmAsia News

Executive Summary

Following the release of the essential drug list and implementation opinion, the formulation of five supplementary documents is being speeded up, say authoritative sources. Expected to come out progressively from late August to November, the documents include an opinion guide on essential drug purchase and distribution, regulations on essential drug application, regulations on essential drug quality supervision, a clinical application guide and a national reserves for essential drugs. The opinion guide on essential drug purchase and distribution, to be out first, is the pivotal component for the system implementation. It will define all essential drug purchase and distribution issues such as: determining whether to have an open online bidding system for purchase or the existing local drug purchase platform; and selection of distributors on the provincial, city or county level. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072571

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel